RIGL

+ Watchlist + Portfolio

Rigel Pharmaceuticals, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $46.96
52-Week Range: $24.95 – $52.24
Market Cap: $845.26M
P/E (TTM): 2.68
EPS (TTM): 16.89
Dividend Yield: —

Advanced Metrics

Price/Book: 1.98
PEG Ratio: —
Return on Equity: 126.90%
Return on Assets: 14.95%
Gross Margin: 75.61%
Operating Margin: 29.95%
Profit Margin: 116.30%
Current Ratio: 1.94
Debt/Equity: 0.09
Total Debt: $39.95M
Free Cash Flow: $-31.76M
Revenue Growth: -22.60%
Earnings Growth: -73.20%
Enterprise Value: $821.83M

RIGL Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$120.24M	$116.88M	$179.28M	$294.28M
Cost of Revenue	$1.75M	$7.11M	$18.65M	$19.62M
Gross Profit	$118.49M	$109.77M	$160.63M	$274.66M
Research & Development	$60.27M	$24.52M	$23.38M	$33.30M
Selling, General & Admin	$112.45M	$105.74M	$113.06M	$115.90M
Operating Expenses	$172.72M	$130.26M	$136.44M	$149.19M
Operating Income	-$54.23M	-$20.49M	$24.19M	$125.47M
EBITDA	-$53.87M	-$16.98M	$28.51M	$131.56M
Pretax Income	-$58.57M	-$25.09M	$18.37M	$121.83M
Income Tax	$0.00	$0.00	$881.00K	-$245.20M
Net Income	-$58.57M	-$25.09M	$17.48M	$367.02M
Diluted EPS	-3.40	-1.44	0.99	19.48
Diluted Shares	17.24M	17.40M	17.69M	18.84M

RIGL Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$24.46M	$32.79M	$56.75M	$40.58M
Receivables	$40.32M	$30.55M	$41.62M	$51.76M
Inventory	$9.12M	$5.52M	$6.00M	$11.51M
Current Assets	$115.90M	$99.27M	$135.10M	$240.17M
Total Assets	$134.28M	$117.22M	$163.98M	$513.59M
Current Liabilities	$65.21M	$53.27M	$63.30M	$99.24M
Long-Term Debt	$39.45M	$52.37M	$52.41M	$22.48M
Total Debt	$41.55M	$60.58M	$59.97M	$53.30M
Total Liabilities	$147.90M	$145.87M	$160.69M	$122.11M
Retained Earnings	-$1.38B	-$1.41B	-$1.39B	-$1.02B
Shareholders' Equity	-$13.62M	-$28.64M	$3.29M	$391.48M
Working Capital	$50.69M	$46.00M	$71.80M	$140.93M
Net Debt	$14.99M	$26.82M	$2.93M	$11.71M

RIGL Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$73.76M	-$5.74M	$31.47M	$75.66M
Capital Expenditure	-$450.00K	-$15.00M	-$396.00K	—
Free Cash Flow	-$74.21M	-$20.74M	$31.07M	$75.66M
Depreciation & Amortisation	$998.00K	$1.24M	$2.23M	$2.42M
Stock-Based Compensation	$12.38M	$8.81M	$12.39M	$12.71M
Investing Cash Flow	$72.78M	-$4.30M	$4.13M	-$92.36M
Financing Cash Flow	$6.55M	$18.37M	-$11.64M	$601.00K
Share Repurchases	$0.00	$0.00	-$10.00M	$0.00
Net Change in Cash	$5.57M	$8.33M	$23.96M	-$16.11M

RIGL Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$53.33M	$101.69M	$69.46M	$69.80M	$58.82M
Cost of Revenue	$4.41M	$4.50M	$4.75M	$5.96M	$4.61M
Gross Profit	$48.92M	$97.18M	$64.71M	$63.85M	$54.21M
Research & Development	$8.44M	$6.82M	$7.35M	$10.69M	$11.68M
Selling, General & Admin	$27.71M	$29.26M	$28.94M	$29.99M	$30.65M
Operating Expenses	$36.15M	$36.08M	$36.29M	$40.68M	$42.33M
Operating Income	$12.77M	$61.10M	$28.42M	$23.17M	$11.88M
EBITDA	$13.97M	$62.46M	$30.12M	$25.01M	$13.69M
Pretax Income	$11.51M	$59.98M	$27.62M	$22.71M	$11.66M
Income Tax	$65.00K	$369.00K	-$280.00K	-$245.35M	$3.00M
Net Income	$11.45M	$59.61M	$27.90M	$268.06M	$8.65M
Diluted EPS	0.63	3.28	1.46	13.54	0.44
Diluted Shares	18.17M	18.16M	19.16M	19.79M	19.69M

RIGL Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$45.73M	$53.41M	$48.53M	$40.58M	$24.41M
Receivables	$41.55M	$39.91M	$45.92M	$51.76M	$49.95M
Inventory	$4.66M	$10.42M	$13.30M	$11.51M	$11.65M
Current Assets	$146.56M	$175.39M	$214.93M	$240.17M	$234.03M
Total Assets	$175.97M	$206.74M	$242.53M	$513.59M	$504.61M
Current Liabilities	$66.63M	$86.64M	$94.40M	$99.24M	$89.49M
Long-Term Debt	$44.93M	$37.45M	$29.97M	$22.48M	$14.99M
Total Debt	$61.07M	$61.04M	$60.88M	$53.30M	$45.72M
Total Liabilities	$157.41M	$124.80M	$124.92M	$122.11M	$104.71M
Retained Earnings	-$1.38B	-$1.32B	-$1.29B	-$1.02B	-$1.01B
Shareholders' Equity	$18.57M	$81.93M	$117.61M	$391.48M	$399.90M
Working Capital	$79.93M	$88.76M	$120.53M	$140.93M	$144.53M
Net Debt	$14.02M	$6.41M	$11.20M	$11.71M	$20.45M

RIGL Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$893.00K	$30.54M	$24.03M	$21.98M	$2.73M
Free Cash Flow	-$893.00K	$30.54M	$24.02M	$21.99M	$2.73M
Depreciation & Amortisation	$604.00K	$607.00K	$603.00K	$601.00K	$597.00K
Stock-Based Compensation	$3.32M	$3.28M	$3.36M	$2.75M	$3.46M
Investing Cash Flow	-$10.55M	-$23.28M	-$33.17M	-$25.36M	-$7.97M
Financing Cash Flow	$484.00K	$418.00K	$4.27M	-$4.57M	-$10.92M
Share Repurchases	$0.00	—	—	—	-$3.74M
Net Change in Cash	-$10.96M	$7.68M	-$4.87M	-$7.95M	-$16.17M

Market Snapshot

About

Rigel Pharmaceuticals is a biotechnology company focused on discovering and developing small molecule drugs for hematologic disorders, cancer, and rare immune diseases. The company has developed approved therapies and maintains a pipeline of clinical and preclinical candidates. Rigel uses its expertise in intracellular signaling pathways to identify novel therapeutic targets.